199 related articles for article (PubMed ID: 24954113)
21. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
22. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding.
Gleeson NC; Buggy F; Sheppard BL; Bonnar J
Acta Obstet Gynecol Scand; 1994 Mar; 73(3):274-7. PubMed ID: 8122512
[TBL] [Abstract][Full Text] [Related]
23. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
24. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
25. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor.
Nielsen VG
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):283-7. PubMed ID: 18469549
[TBL] [Abstract][Full Text] [Related]
26. Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase.
Hayakawa M; Sawamura A; Gando S; Kubota N; Uegaki S; Shimojima H; Sugano M; Ieko M
Surgery; 2011 Feb; 149(2):221-30. PubMed ID: 20655560
[TBL] [Abstract][Full Text] [Related]
27. Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis.
Gitto S; Romanelli RG; Cellai AP; Lami D; Vizzutti F; Abbate R; Margheri F; Fibbi G; Del Rosso M; Laffi G
Intern Emerg Med; 2021 Mar; 16(2):339-347. PubMed ID: 32445164
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
Winkler UH; Schindler AE; Endrikat J; Düsterberg B
Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
[TBL] [Abstract][Full Text] [Related]
29. Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome.
Hoekstra J; Guimarães AH; Leebeek FW; Darwish Murad S; Malfliet JJ; Plessier A; Hernandez-Guerra M; Langlet P; Elias E; Trebicka J; Primignani M; Garcia-Pagan JC; Valla DC; Rijken DC; Janssen HL;
Blood; 2010 Jan; 115(2):388-95. PubMed ID: 19965669
[TBL] [Abstract][Full Text] [Related]
30. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models.
Leenaerts D; Loyau S; Mertens JC; Boisseau W; Michel JB; Lambeir AM; Jandrot-Perrus M; Hendriks D
J Thromb Haemost; 2018 Oct; 16(10):2057-2069. PubMed ID: 30053349
[TBL] [Abstract][Full Text] [Related]
31. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
32. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
Liu YF; Hou N; Shi YJ; Li CX; Gao YJ; Liu LN
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(21):1638-1642. PubMed ID: 37248064
[No Abstract] [Full Text] [Related]
33. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
[TBL] [Abstract][Full Text] [Related]
34. New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R).
Bouma BN; Meijers JC
Semin Hematol; 2004 Jan; 41(1 Suppl 1):13-9. PubMed ID: 14872415
[TBL] [Abstract][Full Text] [Related]
35. Hemostatic status and fibrinolytic response potential at different phases of the menstrual cycle.
Koh SC; Prasad RN; Fong YF
Clin Appl Thromb Hemost; 2005 Jul; 11(3):295-301. PubMed ID: 16015415
[TBL] [Abstract][Full Text] [Related]
36. Aqueous extract from Brownea grandiceps flowers with effect on coagulation and fibrinolytic system.
Pereira B; Brazón J
J Ethnopharmacol; 2015 Feb; 160():6-13. PubMed ID: 25460592
[TBL] [Abstract][Full Text] [Related]
37. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.
Urano T; Suzuki Y; Iwaki T; Sano H; Honkura N; Castellino FJ
Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890
[TBL] [Abstract][Full Text] [Related]
38. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Meltzer ME; Lisman T; de Groot PG; Meijers JC; le Cessie S; Doggen CJ; Rosendaal FR
Blood; 2010 Jul; 116(1):113-21. PubMed ID: 20385790
[TBL] [Abstract][Full Text] [Related]
39. Fibrinolytic activity in utero and bleeding complications with intrauterine contraceptive devices.
Bonnar J; Kasonde K; Haddon M; Hassanein MK; Allington MJ
Br J Obstet Gynaecol; 1976 Feb; 83(2):160-4. PubMed ID: 148902
[TBL] [Abstract][Full Text] [Related]
40. Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects.
Siudut J; Iwaniec T; Plens K; Pieters M; Undas A
Thromb Res; 2021 Jan; 197():1-7. PubMed ID: 33157491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
